Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $0.0.
- Akebia Therapeutics' EPS (Weighted Average and Diluted) rose 10196.81% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 6521.74%. This contributed to the annual value of -$0.33 for FY2024, which is 1879.39% down from last year.
- Latest data reveals that Akebia Therapeutics reported EPS (Weighted Average and Diluted) of $0.0 as of Q3 2025, which was up 10196.81% from $0.0 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.15 during Q2 2022, and its lowest value of -$0.51 during Q2 2021.
- Over the past 5 years, Akebia Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.09 (recorded in 2024), while the average stood at -$0.15.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 340058.75% in 2024, then soared by 13333.33% in 2025.
- Akebia Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.42 in 2021, then soared by 91.61% to -$0.04 in 2022, then skyrocketed by 109.2% to $0.0 in 2023, then tumbled by 3400.59% to -$0.11 in 2024, then skyrocketed by 101.82% to $0.0 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.0 for Q3 2025, versus $0.0 for Q2 2025 and $0.03 for Q1 2025.